The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

II.b

ARDS - Acute lung injury

Publications

Zhou X, Sun C, Wang J, Mao J, Guo H

Rapid fatal pulmonary complications in a Chinese patient after bortezomib treatment for ALK-negative anaplastic large-cell lymphoma.

Clinical lymphoma, myeloma & leukemia. 2010;10(2):152-4

Cañete C, Soley A, Vuelta Arce M, Escoda L

[Pulmonary toxicity after bortezomib].

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2008;32(5):301-2

Chew E, Filshie R, Wei A

Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone.

Leukemia & lymphoma. 2007;48(1):212-3

Ohri A, Arena FP

Severe pulmonary complications in African-American patient after bortezomib therapy.

American journal of therapeutics. 2006;13(6):553-5

Miyakoshi S, Kami M, Yuji K, Matsumura T, Takatoku M, Sasaki M, Narimatsu H, Fujii T, Kawabata M, Taniguchi S, Ozawa K, Oshimi K

Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma.

Blood. 2006;107(9):3492-4